Fall is here, which means respiratory viruses like flu, RSV and COVID are expected to keep spreading as weather cools and more people gather indoors. Luckily, we've got vaccines in stock to help ...

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring ... standalone influenza shot developed by Novavax Inc (NASDAQ:NVAX).

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Respiratory syncytial virus (RSV) is a leading cause ... levels and to elicit a Th1 immune response. Novavax is testing a postfusion F protein vaccine formulated with alum in both older adults ...

Previously, the adjuvanted RSV prefusion F protein-based vaccine had been approved only for adults ages 60 and older. Then in October, the FDA expanded the approval of Pfizer's bivalent RSV ...

All folks age 75 and up are recommended for an RSV vaccine ... Moderna, Pfizer or Novavax. For more on this year's COVID vaccines, read about how Novavax compares to the two mRNA shots.

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

A lot of older adults also need protection against another risky winter virus, RSV. Yes, you can get your flu and COVID ...

A lot of older adults also need protection against another risky winter virus, RSV. Yes, you can get your ... 2 while the Novavax vaccine targets its parent strain, JN.1. Daskalakis said all ...